末消動脈疾患(PAD)治療薬の世界市場予測および分析

◆英語タイトル:PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024
◆商品コード:GDHC118PIDR
◆発行会社(調査会社):GlobalData
◆発行日:2015年10月1日
◆ページ数:404
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD10,995 ⇒換算¥1,121,490見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD21,990 ⇒換算¥2,242,980見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD32,985 ⇒換算¥3,364,470見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、末消動脈疾患(PAD)治療薬の世界市場について調査・分析し、以下の構成でお届けいたします。

・イントロダクション
・末消動脈疾患(PAD)の概要:病因、病態生理、症状
・疫学:リスク要因、併存症、グローバル動向、予測方法、疫学的予測結果
・末消動脈疾患(PAD)の管理:治療概要、主要国における診断、診療状況
・末消動脈疾患(PAD)治療薬の競争状況:製品概要、主要医薬品ブランド分析
・末消動脈疾患(PAD)治療薬市場機会及びアンメット・ニーズ分析
・末消動脈疾患(PAD)治療薬のパイプライン分析:主要国別治験動向、フェーズ別/進捗状況別治験動向、有望な薬剤
・製薬企業動向:戦略動向、主要企業情報
・末消動脈疾患(PAD)治療薬市場展望:世界市場及び主要国の市場規模予測、成長要因、阻害要因
【レポートの概要】

PharmaPoint: Peripheral Artery Disease – Global Drug Forecast and Market Analysis to 2024

Summary

In the 2014 base year, the global PAD market was worth approximately $543.4m, including both branded and generic drugs. By 2024, GlobalData expects that the global PAD market will experience significant expansion, with a Compound Annual Growth Rate (CAGR) of approximately 4.15%, equating to around $816.3m. The dramatic increase in the value of the overall global PAD therapeutics market will be partly attributable to the launch of several PAD drugs currently in late-stage pipeline development, which GlobalData believes have extraordinary potential. These include the novel antithrombotic pharmacological agents, Merck & Co.’s Zontivity (vorapaxar), AstraZeneca’s Brilinta (ticagrelor), and Bayer and Janssen’s (a subsidiary of Johnson & Johnson) Xarelto (rivaroxaban), which have the capacity to reform the antiplatelet and anticoagulatory PAD treatment landscape.

GlobalData believes that the size of the market for pharmacological agents designed to alleviate PAD symptoms, including cilostazol, naftidrofuryl, and pentoxifylline, will diminish throughout the forecast period. GlobalData accredits this diminishing to three factors: first, the advent of advanced revascularization procedures, as characterized by gradual, incremental improvements in success rates over time; second, the fact that current drug treatments, such as the ones mentioned above, display lackluster efficacy, perturbing safety attributes, and inconvenient dosing regimens; and third, the lack of novel, superior, premium-priced, drug therapies in the late stages of the PAD pipeline that could encroach on the patient shares of existing, rival pharmacological treatments.

The overall level of unmet need in the PAD market is high, resulting in a generous amount of room for new entrants to capitalize on. With respect to the first three traditional pillars of PAD treatment – antithrombotic pharmacological agents, lipid-lowering medical therapies, and antihypertensive drugs – the level of unmet need will fall once the current crop of late-phase PAD therapies portrayed in this report arrives onto the market. With respect to drugs that allay the symptoms of PAD, the level of unmet need here is astronomical. Present medical treatments are limited, archaic, and some have restricted availability.

Highlights

Key Questions Answered

- From a clinical standpoint, there is a demand for novel medical therapies that target and relieve the symptoms of PAD in IC and CLI patients. KOLs interviewed by GlobalData expressed a desire for second-generation drug treatments that display superior efficacy and favorable safety profiles compared to existing pharmacological. Environmental unmet needs for this particular indication include physician education, patient awareness, greater screening, and improved guidelines. What other unmet needs exist in this market? Will the drugs under development fulfil the unmet needs of the PAD market?
- The current late-stage PAD pipeline encompasses AstraZeneca’s Brillinta, Bayer/Janssen’s Xarelto and Merck’s Zontivity. Will the late-stage drugs make a significant impact on the PAD market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?

Key Findings

- The major drivers of this expansion in the PAD market will be the advent of novel antithrombotic agents, such as Brilinta and Xarelto, onto the PAD stage, and the increasing prevalence of PAD across all of the 8MM.
- The major global barrier to growth in the PAD market will be the losses of patent protection and market exclusivity on marketed and key pipeline drugs during the forecast period, such as AstraZeneca’s Crestor (rosuvastatin), Sanofi’s Plavix (clopidogrel), Brilinta, and Xarelto.
- The overall level of unmet need in the PAD market is high, resulting in a generous amount of room for new entrants to capitalize on. GlobalData forecasts that once Brilinta and Xarelto, pipeline pharmacological agents currently in late-stage clinical trials for PAD, navigate their way through the regulatory landscape and secure approval for the PAD indication, they will address some of the unmet needs in this area.

Scope

- Overview of peripheral artery disease (PAD), including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized PAD therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PAD therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global PAD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to –
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global PAD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PAD therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global PAD therapeutics market from 2014-2024.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

【レポートの目次】

1 Table of Contents
1 Table of Contents 12
1.1 List of Tables 18
1.2 List of Figures 22
2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 26
2.3 Upcoming Related Reports 26
3 Disease Overview 27
3.1 Etiology and Pathophysiology 28
3.1.1 Etiology 28
3.1.2 Pathophysiology 30
3.2 Classification and Staging Systems 31
3.3 Symptoms and Clinical Presentation 33
3.4 Prognosis 37
3.5 Quality of Life 41
4 Epidemiology 43
4.1 Disease Background 43
4.2 Risk Factors and Comorbidities 44
4.3 Global Trends 46
4.4 Forecast Methodology 47
4.4.1 Sources Used 48
4.4.2 Sources Not Used 61
4.4.3 Forecast Assumptions and Methods 61
4.5 Epidemiological Forecast of Total Prevalent Cases of PAD (2014-2024) 67
4.5.1 Total Prevalent Cases of PAD 67
4.5.2 Age-Specific Total Prevalent Cases of PAD 68
4.5.3 Sex-Specific Total Prevalent Cases of PAD 70
4.5.4 Age-Adjusted Total Prevalence of PAD 72
4.5.5 Total Prevalent Asymptomatic and Symptomatic Cases of PAD 73
4.5.6 Total Prevalent Cases of PAD with Intermittent Claudication and PAD with Critical Limb Ischemia 75
4.5.7 Proportion of Total PAD Cases that Present as Asymptomatic, PAD with Intermittent Claudication, and PAD with Critical Limb Ischemia 77
4.5.8 Total Prevalent Cases of PAD with Hypertension and PAD with Diabetes 78
4.6 Epidemiological Forecast of Diagnosed Prevalent Cases of PAD (2014-2024) 80
4.6.1 Diagnosed Prevalent Cases of PAD 80
4.6.2 Age-Specific Diagnosed Prevalent Cases of PAD 82
4.6.3 Sex-Specific Diagnosed Prevalent Cases of PAD 84
4.6.4 Diagnosed Prevalent Asymptomatic and Symptomatic Cases of PAD 86
4.6.5 Diagnosed Prevalent Cases of PAD with Intermittent Claudication and PAD with Critical Limb Ischemia 88
4.6.6 Proportion of Diagnosed PAD Cases that Present as Symptomatic, PAD with Intermittent Claudication, and PAD with Critical Limb Ischemia 90
4.6.7 Diagnosed Prevalent Cases of PAD with Hypertension and PAD Cases with Diabetes 91
4.7 Discussion 93
4.7.1 Epidemiological Forecast Insight 93
4.7.2 Limitations of the Analysis 94
4.7.3 Strengths of the Analysis 95
5 Disease Management 96
5.1 Diagnosis and Treatment Overview 96
5.1.1 Diagnosis 96
5.1.2 Treatment Guidelines and Leading Prescribed Drugs 100
5.2 US 101
5.3 Five Major European Markets 108
5.4 Japan 118
5.5 Urban China 122
6 Competitive Assessment 128
6.1 Overview 128
6.2 Lifestyle Modifications 132
6.2.1 Exercise 132
6.2.2 Smoking cessation 135
6.3 Risk Factor Modification Drugs 137
6.3.1 Lipid-Lowering Medical Therapies 137
6.3.2 Antihypertensive Medical Therapies 144
6.3.3 Antithrombotic Medical Therapies 151
6.3.4 Glucose-Lowering Medical Therapies 172
6.3.5 Thrombolytic Therapies 175
6.4 Medical Therapies Treating the Symptoms of PAD – Major Brands 176
6.4.1 Pletal / Pletaal (cilostazol) 176
6.4.2 Praxilene (naftidrofuryl oxalate) 190
6.4.3 Trental (pentoxifylline) 196
6.4.4 Prostaglandin and Prostanoid Medical Therapies 205
6.4.5 Other Pharmacological Therapies 209
6.5 Non-Pharmacological Therapies 211
6.5.1 Revascularization 211
7 Unmet Need and Opportunity Analysis 217
7.1 Overview 217
7.2 Enhanced Patient and Physician Education and Awareness of PAD, Facilitating Augmented Diagnosis and Treatment Rates 219
7.2.1 Unmet Need 219
7.2.2 Gap Analysis 226
7.2.3 Opportunity 228
7.3 A Greater Number of Trials Exclusively Involving PAD Patients Will Yield Improved Guidelines for the Management of PAD 233
7.3.1 Unmet Need 233
7.3.2 Gap Analysis 237
7.3.3 Opportunity 238
7.4 Superior Pharmacological Agents that Treat the Symptoms of Intermittent Claudication and Critical Limb Ischemia, but also Obviate Cardiovascular Events 240
7.4.1 Unmet Need 240
7.4.2 Gap Analysis 242
7.4.3 Opportunity 243
7.5 Unravelling the Convoluted Nature Behind the Etiology and Pathophysiology of Atherosclerosis, Which Will Potentially Lead to Treatments that Prevent or Reverse Plaque Formation 247
7.5.1 Unmet Need 247
7.5.2 Gap Analysis 248
7.5.3 Opportunity 248
8 Pipeline Assessment 251
8.1 Overview 251
8.2 Promising Drugs in Late-Stage Clinical Development 253
8.2.1 Xarelto (rivaroxaban) 254
8.2.2 Brilinta (ticagrelor) 270
8.3 Promising Drugs in Early-Stage Clinical Development 286
8.3.1 Therapeutic Angiogenesis 286
9 Current and Future Players 291
9.1 Overview and Trends in Corporate Strategy 291
9.2 Company Profiles 295
9.2.1 Bayer 295
9.2.2 Janssen (Johnson & Johnson) 297
9.2.3 AstraZeneca 299
9.2.4 Merck & Co. 302
9.2.5 Sanofi 303
9.2.6 Pfizer 305
9.2.7 Bristol-Myers Squibb 306
9.2.8 Otsuka Holdings 307
10 Market Outlook 309
10.1 Global Markets 309
10.1.1 Forecast 309
10.1.2 Drivers and Barriers – Global Issues 314
10.2 US 318
10.2.1 Forecast 318
10.2.2 Key Events 322
10.2.3 Drivers and Barriers 322
10.3 Five Major European Markets 326
10.3.1 Forecast 326
10.3.2 Key Events 330
10.3.3 Drivers and Barriers 331
10.4 Japan 341
10.4.1 Forecast 341
10.4.2 Key Events 344
10.4.3 Drivers and Barriers 344
10.5 Urban China 347
10.5.1 Forecast 347
10.5.2 Key Events 350
10.5.3 Drivers and Barriers 350
11 Appendix 354
11.1 Bibliography 354
11.2 Abbreviations 382
11.3 Methodology 387
11.4 Forecasting Methodology 387
11.4.1 Diagnosed PAD Patients 387
11.4.2 Percent Drug-Treated Patients 388
11.4.3 Drugs Included in Each Therapeutic Class 388
11.4.4 Launch and Patent Expiry Dates 388
11.4.5 General Pricing Assumptions 389
11.4.6 Individual Drug Assumptions 390
11.4.7 Generic Erosion 395
11.4.8 Pricing of Pipeline Agents 395
11.5 Physicians and Specialists Included in this Study 396
11.6 About the Authors 400
11.6.1 Analyst 400
11.6.2 Therapy Area Director 400
11.6.3 Epidemiologist 401
11.6.4 Global Head of Healthcare 401
11.6.5 Global Director of Therapy Analysis and Epidemiology 402
11.7 About GlobalData 403
11.8 Disclaimer 403

1.1 List of Tables
Table 1: The Various Causes of PAD 29
Table 2: The Rutherford-Baker System and the Fontaine Classification for PAD 32
Table 3: The Various Etiologies of ALI 33
Table 4: The Symptoms of PAD 37
Table 5: Risk Factors and Comorbidities for PAD 45
Table 6: 8MM, Sources of Epidemiological Data Used to Forecast the Total Prevalent Cases of PAD 48
Table 7: 8MM, Sources of Epidemiological Data Used to Forecast Symptomatic and Asymptomatic Total Prevalent Cases of PAD 49
Table 8: 8MM, Sources of Epidemiological Data Used to Forecast the IC and CLI Total Prevalent Cases of PAD 50
Table 9: 8MM, Sources of Epidemiological Data Used to Forecast Total Prevalent Cases of PAD with Hypertension or Diabetes 51
Table 10: 8MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of PAD 52
Table 11: 8MM, Sources of Epidemiological Data Used to Forecast Asymptomatic and Symptomatic Diagnosed Prevalent Cases of PAD 53
Table 12: 8MM, Sources of Epidemiological Data Used for the Forecast of the Proportion of the Diagnosed PAD Population that Presents with IC 54
Table 13: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of PAD with Hypertension or Diabetes 55
Table 14: 8MM, Total Prevalent Cases of PAD, Both Sexes, Ages ≥35 Years, Select Years, 2014-2024 67
Table 15: 8MM, Age-Specific Total Prevalent Cases of PAD, Both Sexes, N (Row %), 2014 69
Table 16: 8MM, Sex-Specific Total Prevalent Cases of PAD, Ages ≥35 Years, N (Row %), 2014 71
Table 17: 8MM, Total Prevalent Asymptomatic and Symptomatic Cases of PAD, Both Sexes, Ages ≥35 Years, N (Row %), 2014 74
Table 18: 8MM, Total Prevalent Cases of PAD with IC and PAD with CLI, Both Sexes, Ages ≥35 Years, N , 2014 76
Table 19: 8MM, Total Prevalent Cases of PAD with Hypertension and PAD with Diabetes, Both Sexes, Ages ≥35 Years, N (Row %), 2014 79
Table 20: 8MM, Diagnosed Prevalent Cases of PAD, Both Sexes, Ages ≥35 Years, Select Years, 2014-2024 81
Table 21: 8MM, Age-Specific Diagnosed Prevalent Cases of PAD, Both Sexes, N, 2014 83
Table 22: 8MM, Sex-Specific Diagnosed Prevalent Cases of PAD, Ages ≥35 Years, N (Row %), 2014 85
Table 23: 8MM, Diagnosed Prevalent Asymptomatic and Symptomatic Cases of PAD, Both Sexes, Ages ≥35 Years, N (Row %), 2014 87
Table 24: 8MM, Diagnosed Prevalent Cases of PAD with IC or CLI, Both Sexes, Ages ≥35 Years, N , 2014 89
Table 25: 8MM, Diagnosed Prevalent Cases of PAD with Hypertension and PAD with Diabetes, Both Sexes, Ages ≥35 Years, N (Row %), 2014 92
Table 26: Population Characteristics of Individuals who Require Regular Screening for PAD 96
Table 27: Treatment Guidelines for PAD 100
Table 28: 8MM, Most Prescribed Drugs for PAD by Class, 2015 101
Table 29: Country Profile - US 107
Table 30: Country Profile - 5EU 116
Table 31: Country Profile - Japan 121
Table 32: Country Profile - Urban China 125
Table 33: Leading Drugs for PAD Treatment, 2015 132
Table 34: 8MM, Most Frequently Prescribed Lipid-lowering Medical Therapies 143
Table 35: Most Frequently Used Beta Blockers 148
Table 36: Product Profile - Beta Blockers 149
Table 37: Most Frequently Used ACE Inhibitors 149
Table 38: Product Profile - ACE Inhibitors 150
Table 39: Most Frequently Used ARBs 150
Table 40: Product Profile - ARBs 151
Table 41: Product Profile - Plavix (clopidogrel) 155
Table 42: Product Profile - Zontivity (vorapaxar) 164
Table 43: Efficacy and Bleeding Endpoints at Three Years in the TRA 2P-TIMI 50 Study 165
Table 44: Product Profile - Metformin 174
Table 45: Product Profile - Pletal (cilostazol) 184
Table 46: Safety Profile - Pletal (cilostazol) 187
Table 47: SWOT Analysis of Pletal, 2015 188
Table 48: Global Sales Forecast ($m) for Cilostazol, 2014-2024 189
Table 49: Product Profile - Praxilene (naftidrofuryl) 193
Table 50: Safety Profile - Praxilene (naftidrofuryl) 194
Table 51: SWOT Analysis of Praxilene, 2015 195
Table 52: Global Sales Forecast ($) for Naftidrofuryl, 2014-2024 196
Table 53: Product Profile - Trental (pentoxifylline) 200
Table 54: Most Frequently Recorded Side Effects for Pentoxifylline and Cilostazol. 202
Table 55: The Incidence (%) of Side Effects with Trental 203
Table 56: SWOT Analysis of Trental, 2015 204
Table 57: Global Sales Forecast ($m) for Pentoxifylline, 2014-2024 205
Table 58: Indications for Revascularization in PAD 216
Table 59: Major Unmet Needs and Opportunities in PAD 219
Table 60: Promising Drugs in Late-stage Clinical Development in the PAD Pipeline, 2015 253
Table 61: Comparison of Therapeutic Classes in Development for PAD, 2015 254
Table 62: Product Profile - Xarelto (rivaroxaban) 262
Table 63: SWOT Analysis of Xarelto, 2015 268
Table 64: 8MM, Sales Forecast ($m) for Xarelto, 2014-2024 269
Table 65: Product Profile - Brilinta (ticagrelor) 280
Table 66: Brilinta’s Efficacy and Safety Endpoints as Three-Year Kaplan-Meier Estimates in the PEGASUS-TIMI 54 Study 281
Table 67: SWOT Analysis of Brilinta, 2015 285
Table 68: 8MM, Sales Forecast ($) for Brilinta, 2014-2024 286
Table 69: 8MM, Key Companies’ Relevant Key Marketed and Pipeline Drugs in the PAD Market, 2015 294
Table 70: Bayer’s PAD Portfolio Assessment, 2015 297
Table 71: Janssen’s PAD Portfolio Assessment, 2015 299
Table 72: AstraZeneca’s PAD Portfolio Assessment, 2015 301
Table 73: Merck’s PAD Portfolio Assessment, 2015 303
Table 74: Sanofi’s PAD Portfolio Assessment, 2015 304
Table 75: Pfizer’s PAD Portfolio Assessment, 2015 305
Table 76: Bristol-Myers Squibb’s PAD Portfolio Assessment, 2015 307
Table 77: Otsuka Pharmaceutical’s PAD Portfolio Assessment, 2015 308
Table 78: 8MM Sales Forecast ($m) for PAD, 2014-2024 311
Table 79: 8MM, PAD Market - Drivers and Barriers, 2015 314
Table 80: 8MM, Sales Forecast ($m) for PAD in the US, 2014-2024 320
Table 81: Key Events Impacting Sales for PAD in the US, 2014-2024. 322
Table 82: US PAD Market - Drivers and Barriers, 2014-2024. 322
Table 83: Sales Forecast ($m) for PAD in the 5EU, 2014-2024 327
Table 84: Key Events Impacting Sales for PAD in the 5EU, 2014-2024 330
Table 85: 5EU PAD Market - Drivers and Barriers, 2014-2024 331
Table 86: Sales Forecast ($m) for PAD in Japan, 2014-2024 342
Table 87: Key Events Impacting Sales for PAD in Japan, 2014-2024 344
Table 88: PAD Market - Japan Drivers and Barriers, 2014-2024 344
Table 89: Sales Forecasts ($m) for PAD in Urban China, 2014-2024 348
Table 90: Key Events Impacting Sales for PAD in China, 2014-2024 350
Table 91: China PAD Market -Drivers and Barriers, 2014-2024 350
Table 92: Abbreviations 382
Table 93: Key Launch Dates 388
Table 94: Key Patent Expiries 389
Table 95: High-Prescribing Physicians Non-KOLs Surveyed, By Country 399

1.2 List of Figures
Figure 1: Clinical Manifestations of PAD 28
Figure 2: Progression of PAD, Atherosclerotic Plaque Rupture and Thrombosis. 30
Figure 3: 8MM, Patient Flow for the Epidemiological Forecast of PAD 48
Figure 4: 8MM, Total Prevalent Cases of PAD, Both Sexes, Ages ≥35 Years, Select Years, 2014-2024 68
Figure 5: 8MM, Age-Specific Total Prevalent Cases of PAD, Both Sexes, N, 2014 70
Figure 6: 8MM, Sex-Specific Total Prevalent Cases of PAD, Ages ≥35 Years, N, 2014 72
Figure 7: 8MM, Age-Standardized Total Prevalence of PAD, 2014 73
Figure 8: 8MM, Total Prevalent Asymptomatic and Symptomatic Cases of PAD, Both Sexes, Ages ≥35 Years, N, 2014 75
Figure 9: 8MM, Total Prevalent Cases of PAD with IC and PAD with CLI, Both Sexes, Ages ≥35 Years, N, 2014 77
Figure 10: 8MM, Proportion of Total PAD Cases that Present as Asymptomatic, PAD with IC, and PAD with CLI, Both Sexes, Ages ≥35 Years, % 78
Figure 11: 8MM, Total Prevalent Cases of PAD with Hypertension and PAD with Diabetes, Both Sexes, Ages ≥35 Years, N, 2014 80
Figure 12: 8MM, Diagnosed Prevalent Cases of PAD, Both Sexes, Ages ≥35 Years, Select Years, 2014-2024 82
Figure 13: 8MM, Age-Specific Diagnosed Prevalent Cases of PAD, Both Sexes, N, 2014 84
Figure 14: 8MM, Sex-Specific Diagnosed Prevalent Cases of PAD, Ages ≥35 Years, N, 2014 86
Figure 15: 8MM, Diagnosed Prevalent Asymptomatic and Symptomatic Cases of PAD, Both Sexes, Ages ≥35 Years, N, 2014 88
Figure 16: 8MM, Diagnosed Prevalent Cases of PAD with IC or CLI, Both Sexes, Ages ≥35 Years, N, 2014 90
Figure 17: 8MM, Proportion of Diagnosed PAD Cases that Present as Asymptomatic, PAD with IC, and PAD with CLI, Both Sexes, Ages ≥35 Years, %, 2014 91
Figure 18: 8MM, Diagnosed Prevalent Cases of PAD with Hypertension and PAD with Diabetes, Both Sexes, Ages ≥35 Years, N, 2014 93
Figure 19: The Most Common Tests Used to Diagnose PAD in US Patients, 2014 103
Figure 20: Breakdown of US PAD Patients by Percentage (%) Predominantly Treated in Primary or Specialist Healthcare Settings, 2014 104
Figure 21: The Most Common Tests Used to Diagnose PAD in 5EU Patients, 2014 112
Figure 22: Breakdown of 5EU PAD Patients by Percentage (%) Predominantly Treated in Primary or Specialist Healthcare Settings, 2014 113
Figure 23: The Most Common Tests Used to Diagnose PAD Patients in Japan, 2014 119
Figure 24: Percentage (%) Breakdown of Japan PAD Patients by Percentage (%) Predominantly Treated in Primary or Specialist Healthcare Settings, 2014 120
Figure 25: The Most Common Tests Used to Diagnose PAD Patients in China, 2014 123
Figure 26: Breakdown of Chinese PAD Patients by Percentage (%) Predominantly Treated in Primary or Specialist Healthcare Settings, 2014 124
Figure 27: 8MM, Percentage (%) of PAD Patients Referred to Specialist Secondary or Tertiary Care by Primary Care Physicians, 2014 127
Figure 28: The Various Marketed and Pipeline Antithrombotic Medical Therapies for PAD 152
Figure 29: The Treatment Algorithm for IC Patients 169
Figure 30: The Treatment Algorithm for CLI Patients 170
Figure 31: The Treatment Algorithm for ALI Patients 171
Figure 32: Competitive Assessment of Late-Stage Pipeline Agents in PAD, 2014-2024 253
Figure 33: Company Portfolio Gap Analysis in PAD, 2014-2024 295
Figure 34: Global Sales for PAD by Region, 2014 and 2024 312
Figure 35: 8MM, Global PAD Sales by Drug Class, 2014 and 2024 313
Figure 36: Sales for PAD in the US by Drug Class, 2014 and 2024 321
Figure 37: Sales for PAD in the 5EU by Drug Class, 2014 and 2024 329
Figure 38: Sales for PAD in Japan by Drug Class, 2014 and 2024 343
Figure 39: Sales for PAD in China by Drug Class, 2014 and 2024 349

【掲載企業】

Bayer
Janssen (Johnson & Johnson)
AstraZeneca
Merck & Co.
Sanofi
Pfizer
Bristol-Myers Squibb
Otsuka Holdings

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[末消動脈疾患(PAD)治療薬の世界市場予測および分析]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。H&I文字はH&Iグローバルリサーチ株式会社の商標(登録第5783645号)です。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。
※当サイトでは2016年06月29日現在 193,799 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆